LymphedemaV1, Main, Exploration, bibRecord, 004B16

Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100)

Identifieur interne : 004B16 ( Main/Exploration ); précédent : 004B15; suivant : 004B17

Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100)

Auteurs : David Cella ; Molin Wang ; Lynne Wagner ; Kathy Miller

Source :

Breast cancer research and treatment [ 0167-6806 ] ; 2011.

RBID : PMC:3684040

Abstract

The purpose of this study was to examine health-related quality of life (HRQL) among women with metastatic breast cancer treated on E2100 with paclitaxel or paclitaxel plus bevacizumab. Trial participants (N = 670) completed the Functional Assessment of Cancer Therapy-Breast (FACT-B) pre-treatment and following 4 and 8 cycles of treatment to assess HRQL and breast cancer-specific concerns. A significantly higher proportion of missing FACT-B assessments was observed among patients receiving paclitaxel only, due to faster time to death. To account for this non-ignorable pattern of missing data, we conducted a survival-adjusted HRQL analysis by jointly modeling the longitudinal HRQL outcome and time to non-ignorable dropout using a two-stage model. FACT scores assessing HRQL did not differ following 4 and 8 cycles of treatment; however mean scores on the 9-item Breast Cancer Scale were significantly higher after 4 and 8 cycles of treatment among patients receiving paclitaxel plus bevacizumab. No differences were observed between treatment arms on FACT-B total scores. The addition of bevacizumab was not associated with additional side effect burden from the patient perspective and was associated with a greater reduction in breast cancer-specific concerns. No other differences were noted.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684040

DOI: 10.1007/s10549-011-1725-6
PubMed: 21874312
PubMed Central: 3684040

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100)</title>
<author><name sortKey="Cella, David" sort="Cella, David" uniqKey="Cella D" first="David" last="Cella">David Cella</name>
</author>
<author><name sortKey="Wang, Molin" sort="Wang, Molin" uniqKey="Wang M" first="Molin" last="Wang">Molin Wang</name>
</author>
<author><name sortKey="Wagner, Lynne" sort="Wagner, Lynne" uniqKey="Wagner L" first="Lynne" last="Wagner">Lynne Wagner</name>
</author>
<author><name sortKey="Miller, Kathy" sort="Miller, Kathy" uniqKey="Miller K" first="Kathy" last="Miller">Kathy Miller</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">21874312</idno>
<idno type="pmc">3684040</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684040</idno>
<idno type="RBID">PMC:3684040</idno>
<idno type="doi">10.1007/s10549-011-1725-6</idno>
<date when="2011">2011</date>
<idno type="wicri:Area/Pmc/Corpus">003745</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">003745</idno>
<idno type="wicri:Area/Pmc/Curation">003744</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">003744</idno>
<idno type="wicri:Area/Pmc/Checkpoint">002D20</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002D20</idno>
<idno type="wicri:Area/Ncbi/Merge">004623</idno>
<idno type="wicri:Area/Ncbi/Curation">004623</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004623</idno>
<idno type="wicri:doubleKey">0167-6806:2011:Cella D:survival:adjusted:health</idno>
<idno type="wicri:Area/Main/Merge">004B48</idno>
<idno type="wicri:Area/Main/Curation">004B16</idno>
<idno type="wicri:Area/Main/Exploration">004B16</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100)</title>
<author><name sortKey="Cella, David" sort="Cella, David" uniqKey="Cella D" first="David" last="Cella">David Cella</name>
</author>
<author><name sortKey="Wang, Molin" sort="Wang, Molin" uniqKey="Wang M" first="Molin" last="Wang">Molin Wang</name>
</author>
<author><name sortKey="Wagner, Lynne" sort="Wagner, Lynne" uniqKey="Wagner L" first="Lynne" last="Wagner">Lynne Wagner</name>
</author>
<author><name sortKey="Miller, Kathy" sort="Miller, Kathy" uniqKey="Miller K" first="Kathy" last="Miller">Kathy Miller</name>
</author>
</analytic>
<series><title level="j">Breast cancer research and treatment</title>
<idno type="ISSN">0167-6806</idno>
<idno type="eISSN">1573-7217</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="P1">The purpose of this study was to examine health-related quality of life (HRQL) among women with metastatic breast cancer treated on E2100 with paclitaxel or paclitaxel plus bevacizumab. Trial participants (<italic>N</italic>
 = 670) completed the Functional Assessment of Cancer Therapy-Breast (FACT-B) pre-treatment and following 4 and 8 cycles of treatment to assess HRQL and breast cancer-specific concerns. A significantly higher proportion of missing FACT-B assessments was observed among patients receiving paclitaxel only, due to faster time to death. To account for this non-ignorable pattern of missing data, we conducted a survival-adjusted HRQL analysis by jointly modeling the longitudinal HRQL outcome and time to non-ignorable dropout using a two-stage model. FACT scores assessing HRQL did not differ following 4 and 8 cycles of treatment; however mean scores on the 9-item Breast Cancer Scale were significantly higher after 4 and 8 cycles of treatment among patients receiving paclitaxel plus bevacizumab. No differences were observed between treatment arms on FACT-B total scores. The addition of bevacizumab was not associated with additional side effect burden from the patient perspective and was associated with a greater reduction in breast cancer-specific concerns. No other differences were noted.</p>
</div>
</front>
</TEI>
<affiliations><list></list>
<tree><noCountry><name sortKey="Cella, David" sort="Cella, David" uniqKey="Cella D" first="David" last="Cella">David Cella</name>
<name sortKey="Miller, Kathy" sort="Miller, Kathy" uniqKey="Miller K" first="Kathy" last="Miller">Kathy Miller</name>
<name sortKey="Wagner, Lynne" sort="Wagner, Lynne" uniqKey="Wagner L" first="Lynne" last="Wagner">Lynne Wagner</name>
<name sortKey="Wang, Molin" sort="Wang, Molin" uniqKey="Wang M" first="Molin" last="Wang">Molin Wang</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004B16 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004B16 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     PMC:3684040
   |texte=   Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100)
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:21874312" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

Serveur d'exploration sur le lymphœdème

Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100)

Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100)

Source :

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.